Dyskinesia News and Research

RSS

Parkinson's disease pivotal trial treats first patient using focused ultrasound

The first patient in a multicenter pivotal trial using focused ultrasound to address the major motor symptoms of Parkinson's disease has been treated at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center in New York.

27 Apr 2018

New study to test safety, efficacy of MRI-guided focused ultrasound to treat Parkinson's disease

University of Maryland Medicine is leading a phase 3 study to test the safety and efficacy of using MRI-guided focused ultrasound on the brain in order to treat Parkinson's disease.

13 Feb 2018

Gladstone scientists uncover how fast-spiking interneurons improve procedural learning

Even if you haven't ridden your bike in years, you probably remember how to do so without giving it much thought.

9 Feb 2018

Scientists test new tactic for controlling motor complications in Parkinson's disease

Standard drug treatment for Parkinson's disease can over time induce motor complications that reduce the effectiveness of restoring mobility.

27 Jan 2018

Researchers uncover molecular roots of genetic lung disease

Respiratory infections peak during the winter months, and most people recover within a few weeks. But for those with a rare genetic lung disease, the sniffling, coughing and congestion never end.

24 Jan 2018

UK-based charity to accelerate development of promising new drug for Parkinson's

UK-based charity, Parkinson's UK is set to provide more than $1million in funding to US biotech company, Neurolixis, to accelerate the development of a promising new drug for people with Parkinson's.

24 Jan 2018

Study identifies new target for treatment of depression

According to the World Health Organization more than three hundred million people worldwide are affected by major depressive disorder. Unfortunately, the antidepressants commonly used to treat them only work for 50% of the population.

18 Jan 2018

Deep brain stimulation may improve survival for Parkinson's patients

A treatment called deep brain stimulation (DBS) could extend the life of people with Parkinson's disease. Researchers at the Edward Hines, Jr. VA Hospital in Illinois found that patients who received stimulation via an implanted device had a modest survival advantage compared with those treated with medication only.

21 Dec 2017

Sonic Hedgehog helps solve mysteries of Parkinson's disease

You may know Sonic Hedgehog as a Sega videogame character who saves us all from world domination. But within the realm of science, Sonic Hedgehog is also helping to solve the mysteries of Parkinson's Disease.

28 Oct 2017

New approaches to prevent or treat antipsychotic-induced supersensitivity psychosis

In the current issue of Psychotherapy and Psychosomatic, professor Guy Chouinard, one of the most important psychopharmacologists, provides a synthesis of the data that are concerned with neglected side effects of commonly used psychotropic drugs.

8 Sep 2017

New drug may limit disease progression, provide better symptom relief to Parkinson's patients

Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.

31 Jul 2017

Apomorphine infusion found to be effective treatment for Parkinson’s patients with motor fluctuations

Apomorphine subcutaneous infusion is an effective treatment for Parkinson patients whose motor fluctuations are poorly controlled by conventional therapies.

28 Jun 2017

FDA grants approval for first drug to treat adults with tardive dyskinesia

The U.S. Food and Drug Administration today approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition.

11 Apr 2017

New drug can reduce tardive dyskinesia in patients with schizophrenia, mood disorder

Antipsychotic treatment can cause involuntary movements such as lip smacking, tongue protrusions and excessive eye blinking. These movements typically occur after more than 3 months of treatment and are called tardive dyskinesia.

7 Apr 2017

FDA approves drug as add-on treatment for Parkinson's disease patients

The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson's disease who are currently taking levodopa/carbidopa and experiencing "off" episodes.

21 Mar 2017

New infusion therapy may help avoid debilitating symptoms in Parkinson's disease patients

Constant infusion of a drug now used intermittently to "rescue" patients with Parkinson's from bouts of immobility may also help avoid these debilitating symptoms and smooth out their movement throughout the day, physician-scientists say.

14 Feb 2017

UAB researchers uncover vital mechanism for L-DOPA-induced-dyskinesia

Though the drug levodopa can dramatically improve Parkinson's disease symptoms, within five years one-half of the patients using L-DOPA develop an irreversible condition -- involuntary repetitive, rapid and jerky movements.

29 Jul 2016

Defects in cerebrospinal fluid flow may contribute to scoliosis during adolescence

A new study in zebrafish suggests that irregular fluid flow through the spinal column brought on by gene mutations is linked to a type of scoliosis that can affect humans during adolescence.

13 Jun 2016

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2015.

12 Feb 2016

Opicapone simplifies levodopa-related motor fluctuation treatment

Once-daily opicapone is effective for the treatment of end-of-dose motor fluctuations in patients receiving levodopa for Parkinson’s disease, phase III study findings show.

23 Dec 2015